Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR® trial by Dusser, Daniel et al.
Syddansk Universitet
Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR®
trial
Dusser, Daniel; Wise, Robert A; Dahl, Ronald; Anzueto, Antonio; Carter, Kerstine; Fowler,
Andy; Calverley, Peter MA
Published in:
The International Journal of Chronic Obstructive Pulmonary Disease (Print)
DOI:
10.2147/COPD.S97924
Publication date:
2016
Document version
Final published version
Document license
CC BY-NC
Citation for pulished version (APA):
Dusser, D., Wise, R. A., Dahl, R., Anzueto, A., Carter, K., Fowler, A., & Calverley, P. M. A. (2016). Differences in
outcomes between GOLD groups in patients with COPD in the TIOSPIR® trial. The International Journal of
Chronic Obstructive Pulmonary Disease (Print), 11(1), 133—145 . DOI: 10.2147/COPD.S97924
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Apr. 2017
© 2016 Dusser et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of COPD 2016:11 133–145
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
133
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/COPD.S97924
Differences in outcomes between GOLD groups 
in patients with COPD in the TIOSPIR® trial
Daniel Dusser1
Robert A Wise2
Ronald Dahl3
Antonio Anzueto4,5
Kerstine Carter6
Andy Fowler7
Peter M Calverley8
1Service de Pneumologie, Hôpital 
Cochin, AP-HP, Université Paris 
Descartes, Sorbonne Paris Cité, Paris, 
France; 2Asthma and Allergy Center, 
Johns Hopkins University School 
of Medicine, Baltimore, MD, USA; 
3Allergy Centre, Odense University 
Hospital, Odense C, Denmark; 
4Pulmonary/Critical Care, University 
of Texas, 5South Texas Veterans 
Health Care System, San Antonio, 
TX, USA; 6Boehringer Ingelheim 
Pharmaceuticals Inc, Ridgefield, CT, 
USA; 7Boehringer Ingelheim Pharma 
Ltd, Bracknell, UK; 8Institute of Ageing 
and Chronic Disease, University of 
Liverpool, Liverpool, UK
Background: The aim of this study was to evaluate whether Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) classification could predict mortality risk factors and 
whether baseline treatment intensity would relate to mortality within each group, using data 
from TIOSPIR®, the largest randomized clinical trial in COPD performed to date.
Methods: A total of 17,135 patients from TIOSPIR® were pooled and grouped by GOLD 
grading (A–D) according to baseline Medical Research Council breathlessness score, exacer-
bation history, and spirometry. All-cause mortality and adjudicated cardiovascular (CV) and 
respiratory mortality were assessed.
Results: Of the 16,326 patients classified, 1,248 died on treatment. Group B patients received 
proportionally more CV treatment at baseline. CV mortality risk, but not all-cause mortality 
risk, was significantly higher in Group B than Group C patients (CV mortality – hazard ratio 
[HR] =1.74, P=0.004; all-cause mortality – HR =1.18, P=0.11). Group D patients had a higher inci-
dence of all-cause mortality than Group B patients (10.9% vs 6.6%). Similar trends were observed 
regardless of respiratory or CV medication at baseline. In contrast, respiratory deaths increased 
consistently from Groups A–D (0.3%, 0.8%, 1.6%, and 4.2% of patients, respectively).
Conclusion: The data obtained from the TIOSPIR® trial, supporting earlier studies, suggest that 
proportionally more CV medication and CV deaths occur in GOLD Group B COPD patients, 
although deaths attributed to respiratory causes are more prevalent in Groups C and D.
Keywords: TIOSPIR®, GOLD, cardiovascular comorbidity, mortality, respiratory death, 
cardiovascular death
Introduction
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) provides 
guidelines for current COPD management and is used by practicing clinicians 
worldwide.1 In 2011, the GOLD grading system changed from the previous I–IV grad-
ing to the current A–D system (last updated in early 2015). This system distinguishes 
between four categories of patients with COPD based on the assessment of symptoms, 
severity of airflow limitation using spirometry, and exacerbation risk: A = low risk, 
fewer symptoms; B = low risk, more symptoms; C = high risk, fewer symptoms; and 
D = high risk, more symptoms; where risk is defined by forced expiratory volume in 
1 second (FEV
1
) levels and/or exacerbation history and severity.2 One of the goals of 
this clinical classification was to identify different populations of COPD patients with 
differing risks of future events and hence, stratify therapy appropriately.
Subsequent data from observational cohorts and population-based studies have 
suggested that despite having better spirometry, Group B patients have a higher risk 
of death and have more cardiovascular (CV) comorbidity than Group C patients.3,4 The 
authors suggested that the 2011 GOLD A–D classification provided a more enhanced 
prediction of exacerbations than the GOLD 2007 I–IV classification, and highlighted 
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the role of dyspnea as a strong predictor of poor survival in 
patients with COPD. However, in these studies, the number 
of patients attributed to Group C was relatively modest 
compared to the overall population, and the cause of death 
was not reported or adjudicated – a problem in patients with 
COPD whose diagnosis is often omitted from routine death 
certification.5 In COPD, the intensity of treatment is often 
considered as a marker of disease severity, but the relation-
ship, if any, of treatment use to outcome within individual 
GOLD groups has so far not been explored.
In this report, we have used data from the TIOSPIR® 
study,6,7 the largest randomized clinical trial in COPD per-
formed to date, to investigate the ability of different GOLD 
groups to predict important clinical outcomes in COPD. Spe-
cifically, we anticipated that there would be differences in the 
risk of death, the causes of death, and hospitalizations between 
the groups, and that baseline treatment intensity would relate 
to mortality within each group. As there were no differences 
in mortality or exacerbation rate between treatment arms in 
the trial, we have pooled the data in this analysis.
Methods
The TIOSPIR® methods have been described previously, 
and the complete study protocol is available online (http://
www.nejm.org/action/showSupplements?doi=10.1056%2F
NEJMoa1303342&viewType=Popup&viewClass=Suppl).6,7 
This study’s protocol and procedures were approved by 
the Institutional Review Board (IRB), Independent Ethics 
Committee (IEC), and competent authority (CA) accord-
ing to national and international regulations. The trial was 
conducted in compliance with the protocol, the principles 
laid down in the Declaration of Helsinki, in accordance with 
the ICH Harmonised Tripartite Guideline for Good Clinical 
Practice (GCP) and in accordance with applicable regulatory 
requirements. All patients provided written informed consent 
prior to participation.
Study population
TIOSPIR® was an event-driven, randomized, double-blind, 
parallel-group trial of 17,135 patients with COPD. We recruited 
patients aged 40 years with a clinical diagnosis of COPD, 
10 pack years of smoking history, a post-bronchodilator 
FEV
1
/forced vital capacity (FVC) ratio 0.70, and an FEV
1
 
70% predicted. Patients with concomitant cardiac disease 
were included except for those with unstable (requiring new 
treatment within last 12 months) or recent events (within last 6 
months). Patients with other clinically significant lung diseases 
or a COPD exacerbation within the past month, moderate or 
severe renal impairment, or those with cancer requiring therapy 
within the past 5 years were excluded. All COPD medications, 
except other inhaled anticholinergics, were allowed. Patients 
were randomized to once-daily 2.5 µg of tiotropium Respimat® 
(Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim 
am Rhein, Germany), 5 µg of tiotropium Respimat®, or 18 µg 
of tiotropium HandiHaler®. (Boehringer Ingelheim Pharma 
GmbH & Co. KG)
Study design
TIOSPIR® participants were free of exacerbation for 4 weeks 
before randomization and were seen every 12 weeks thereafter. 
At randomization, they recorded their degree of breathlessness 
(modified Medical Research Council [mMRC] score) and 
whether they had received antibiotics or systemic steroids 
in the preceding year. All regular medication use, including 
respiratory and CV therapy, was noted. Statin use was not 
assigned as a CV therapy. No record of prior COPD hospital-
ization was obtained. Pre- or post-bronchodilator spirometry 
was performed at this visit or a value recorded in the preced-
ing 6 months was obtained from the case records. The trial 
was closed when at least 1,266 deaths were known to have 
occurred. Vital status was known in 99.7% of cases and the 
cause of death was adjudicated by an independent clinical end-
point committee (see details in Appendix 3 of Wise et al6).
Patients across the treatment arms were pooled and 
divided into groups according to the GOLD 2011 guideline 
classification of A–D,2 according to baseline mMRC dyspnea 
score (while on baseline therapy), exacerbations in year prior 
to the trial (based on antibiotic/systemic steroid use), and 
post-bronchodilator FEV
1
.1 Patients were included in the 
analysis if all these data were available.
Statistical analysis
For patients classified into the GOLD Groups A–D, we exam-
ined patient baseline characteristics and all-cause mortality, 
including respiratory and CV deaths, major adverse CV 
events (MACE; defined as stroke, myocardial infarction [MI], 
sudden death, cardiac death, sudden cardiac death, or fatal 
event in system organ classes for cardiac and vascular dis-
orders), fatal MACE, MI events (including fatal events), and 
hospitalized exacerbations occurring during the trial. Data by 
GOLD Stages I/II–IV were obtained for comparison.
Data are presented as mean (standard deviation [SD]) 
unless otherwise stated. Hazard ratios (HRs) and P-values 
were calculated based on Cox regression by GOLD 2011 
groups (or GOLD Stage). No other covariates were included 
in the model. Only patients who had both GOLD 2011 group 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
27
-J
an
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
135
TIOSPIR® outcomes by GOLD group
and GOLD Stage assigned were included, and patients with 
post-bronchodilator FEV
1
/FVC 70% were excluded. As 
this was an exploratory post hoc analysis, no nominal levels 
of significance were assessed between groups.
Results
Baseline characteristics
Data were available for 16,326 patients. They were clas-
sified into one of the 2011 GOLD groups: 3,594 (22.0%), 
2,879 (17.6%), 3,534 (21.6%), and 6,319 (38.7%) patients 
in Groups A–D, respectively. The mean duration of 
follow-up in this population was similar between the 
groups (Table 1). Table S1 shows the shift of patients from 
GOLD Stages I–IV to GOLD Groups A–D, based on the 
GOLD 2011 classification.
Patient baseline demographics by GOLD group (A–D) are 
shown in Table 1. Mean age and body mass index were similar 
across GOLD groups, although numerically higher in Group B 
patients. Overall, 71.5% of patients were male, with Group B 
having a lower ratio of male to female patients (64.8% male) 
compared with Group C (74.0% male). Race distribution was 
similar across GOLD Groups A, B, and D; Group C had a higher 
ratio of Asian to white patients. COPD duration increased from 
6.3 to 8.3 years for Groups A–D, while smoking history was 
longest in Group B and shortest in Group C. Previous history 
of CV disease was highest in Groups B and D. The percentage 
of male patients increased from GOLD Stage I/II (67.6%) to 
IV (81.7%), as did the proportion of Asian patients (10.5% in 
Stage I/II; 24.0% in Stage IV), while CV history was similar 
across stages (Table S2).
The percentage of patients using pulmonary medication 
combinations at baseline increased from GOLD Groups 
A–D (Table 2). Proportionally more patients from Groups C 
and D used double therapy with long-acting β
2
-agonists 
(LABAs) and inhaled corticosteroids (ICSs) or triple therapy 
(long-acting muscarinic antagonists [LAMAs], LABA, 
and ICS) at baseline than those from Groups A and B. 
Furthermore, a higher proportion of Group A patients used 
LAMAs only (without LABA and ICS) compared to the other 
GOLD groups (Table 2).
A wide range of CV medication was taken at baseline, 
with over 50% of each group using one or more CV therapy, 
and did not increase proportionally from GOLD Groups A–D 
(Table 2). Compared to any other GOLD group, Group B 
had proportionally more patients using one, two, three, four, 
or more CV medications at baseline while Group C patients 
used the least (Figure 1). These medications included more 
calcium channel blockers, angiotensin-converting enzyme 
inhibitors, angiotensin II receptor blockers, acetylsalicylic 
acid, and nitrates than in any other group (Table 2). GOLD 
Group A, however, used the most β-blockers at baseline. 
Using the old GOLD Stage I–IV classification, it was found 
Table 1 Patient baseline characteristics by GOLD group
Baseline characteristic GOLD group
A (N=3,594) B (N=2,879) C (N=3,534) D (N=6,319)
Follow-up duration (days), mean (SD) 853 (123.1) 846 (140) 845 (133) 821 (163)
Post-BD FEV1 (L), mean (SD)
Predicted (%), mean (SD)
1.709 (0.407)
60.6 (6.4)
1.589 (0.405)
59.6 (6.2)
1.189 (0.398)
42.0 (11.1)
1.075 (0.372)
38.99 (11.39)
Post-BD FVC (L), mean (SD)
Ratio of FEV1 to FVC
3.126 (0.820)
0.556 (0.084)
2.908 (0.796)
0.556 (0.086)
2.598 (0.824)
0.468 (0.106)
2.448 (0.774)
0.449 (0.110)
Sex
Male 2,542 (70.7) 1,866 (64.8) 2,615 (74.0) 4,647 (73.5)
Race
White
Black
Asian
Unknown
3,130 (87.1)
41 (1.1)
375 (10.4)
48 (1.3)
2,490 (86.5)
47 (1.6)
297 (10.3)
45 (1.6)
2,676 (75.7)
55 (1.6)
672 (19.0)
131 (3.7)
5,084 (80.5)
100 (1.6)
956 (15.1)
179 (2.8)
Age (years), mean (SD) 64.4 (9.2) 66.3 (9.3) 64.4 (8.8) 65.1 (8.9)
BMI (kg/m2), mean (SD) 26.7 (5.3) 27.7 (5.9) 25.3 (5.1) 25.7 (5.9)
Current smoker 1,491 (41.5) 1,114 (38.7) 1,345 (38.1) 2,265 (35.8)
Smoking history (pack years), mean (SD) 43.1 (24.1) 45.1 (26.2) 42.8 (24.5) 44.3 (24.7)
Medical history
Stroke
MI
IHD/CAD
Cardiac arrhythmia
86 (2.4)
186 (5.2)
461 (12.8)
334 (9.3)
84 (2.9)
215 (7.5)
496 (17.2)
346 (12.0)
69 (2.0)
197 (5.6)
408 (11.5)
335 (9.5)
136 (2.2)
392 (6.2)
1,160 (18.4)
738 (11.7)
Note: Data are n (%) unless otherwise stated. 
Abbreviations: BD, bronchodilator; BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; IHD/CAD, ischemic heart disease/coronary artery disease; MI, myocardial infarction; SD, standard deviation.
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that GOLD Stage I/II patients received more CV medication 
at baseline than Stage III or IV patients (Table S3).
Cardiovascular and respiratory events
Compared to Group A, there was no increased risk of MACE 
during the trial for patients in Group B or C, but the risk 
was significantly higher in Group D (HR =1.23, P=0.10 for 
Group B; HR =0.91, P=0.45 for Group C; HR =1.30, P=0.02 
for Group D) (Table 3). Compared to Group C, Groups B and D 
both experienced significantly more MACE (HR =1.36, 
P=0.02 for Group B; HR =1.43, P=0.002 for Group D). 
MI occurrence in Groups B–D was proportionally similar 
to that of patients in Group A, although Group D patients 
had a significantly higher risk of MI than Group C patients 
(HR =1.56, P=0.04). These data are supported by Kaplan–
Meier curves showing that patients in GOLD Groups A and 
C had a lower risk of MACE than those in Groups B and 
D (Figure 2). Patients from the old GOLD Stage III and IV 
did not have increased risks of MACE or MI compared to 
GOLD Stage I/II patients (Table S4, Figure S1). The number 
of patients with hospitalized exacerbations during the trial 
increased proportionally from GOLD Groups A–D and from 
GOLD Stages I/II–IV (Table 3 and Table S4; Figure 2 and 
Figure S1).
Mortality by GOLD classification
All-cause mortality
All-cause mortality did not increase consistently from GOLD 
Groups A–D (Figure 2). There were proportionally more 
deaths from any cause in Group B (6.6%) than in Groups A 
(4.8%) and C (5.6%) (HR =1.39, P=0.002 vs Group A; 
HR =1.18, P=0.11 vs Group C), although Group D had the 
highest death rate in total (10.9%) (Table 3, Figure 2). In the 
old GOLD stage classification, patients in Stage I/II had a 
lower risk of all-cause death than patients in Stages III and IV 
(Table S4, Figure S1).
Table 2 Type of baseline pulmonary and CV medication use categorized by GOLD group
Baseline medication GOLD group
A (N=3,594) B (N=2,879) C (N=3,534) D (N=6,319)
Patients with pulmonary medication 3,155 (87.8) 2,622 (91.1) 3,145 (89.0) 5,914 (93.6)
LAMA (without LABA and ICS) 538 (15.0) 368 (12.8) 336 (9.5) 453 (7.2)
LABA and ICS (without LAMA) 1,605 (44.7) 1,366 (47.4) 1,931 (54.6) 3,621 (57.3)
LABA + ICS + LAMA (triple therapy) 911 (25.4) 723 (25.1) 1,122 (31.8) 2,053 (32.5)
Patients with CV medication 1,886 (52.5) 1,662 (57.7) 1,646 (46.6) 3,185 (50.4)
β-Blockers 632 (17.6) 483 (16.8) 442 (12.5) 805 (12.7)
Calcium channel blockers 634 (17.6) 600 (20.8) 558 (15.8) 1,109 (17.6)
ACE inhibitors 792 (22.0) 712 (24.7) 611 (17.3) 1,301 (20.6)
ARBs 468 (13.0) 388 (13.5) 362 (10.2) 628 (9.9)
Acetylsalicylic acid 743 (20.7) 627 (21.8) 628 (17.8) 1,171 (18.5)
Nitrates 121 (3.4) 166 (5.8) 83 (2.3) 312 (4.9)
Notes: Data are n (%). The group with the largest proportion is shown in bold.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CV, cardiovascular; GOLD, Global Initiative for Chronic Obstructive Lung 
Disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Figure 1 Patient baseline CV medication use categorized by GOLD group.
Abbreviations: CV, cardiovascular; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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Respiratory deaths
The proportion of respiratory deaths increased consistently 
from Groups A–D, with more respiratory deaths in Groups D 
(4.2%) and C (1.6%) than in Groups B (0.8%) and A (0.3%) 
(Table 3, Figure 2). Group B patients had nearly 50% lower 
risk of death from respiratory causes than Group C patients 
(HR =0.49, P=0.005), and a 2.5-fold higher risk than Group A 
patients (HR =2.52, P=0.01).
CV deaths
Similarly to the results observed for all-cause mortality, the risk 
of death from MACE in Group B was 83% higher than in Group 
A (HR =1.83, P=0.002) and 74% higher than in Group C (HR 
=1.74, P=0.004) (Table 3, Figure 2). Patients in Group D also 
had a higher risk of death from MACE than patients in Groups 
A and C (Table 3, Figure 2). The proportion of patients who 
died from MI was very small (0.2% in Groups B and D, 0.1% 
in Group A, and 0 patients in Group C) (Table 3). Using the old 
GOLD stage classification, it was found that the risk of death 
from MACE was significantly higher in GOLD Stage IV patients 
than in GOLD Stage I/II patients (Table S4, Figure S1).
Mortality by GOLD classification and by 
pulmonary and cardiac baseline therapy
The proportionally higher all-cause mortality observed 
for Group B patients persisted regardless of the baseline 
pulmonary or CV medication received (Table 4). In Group B, 
6.5% of patients with LAMA only and 7.6% with triple 
therapy at baseline died compared to 5.6% (LAMA only) and 
4.4% (triple therapy) for Group A. Similarly, CV therapy at 
baseline did not affect the proportionally higher mortality in 
Group B patients (7.8% [with any CV therapy at baseline] 
and 5.0% [without CV therapy at baseline] of patients in 
Group B died, compared to 5.7% [with any CV therapy 
at baseline] and 3.8% [without CV therapy at baseline] in 
Group A). These differences reached statistical significance 
in patients with triple therapy and those with CV therapy at 
baseline (Table 4).
In the old GOLD stage classification, the risk of all-cause 
death increased from Stage I/II–IV, irrespective of baseline 
pulmonary or CV therapy (Table S5).
Discussion
The data obtained from the TIOSPIR® trial support results 
from earlier studies indicating that there are differences 
in CV medication use and proportionately more all-cause 
deaths, driven by CV deaths, in COPD patients from GOLD 
Group B than Group C.3 This trend persisted regardless 
of the kind of therapy (pulmonary or CV) received at 
baseline. Of the 16,326 patients from TIOSPIR® clas-
sified according to the 2011 GOLD A–D groups, 1,248 
died during the study. As expected, due to disease severity 
Table 3 CV outcomes and patient mortality by GOLD group
Deaths and outcomes GOLD group
A (N=3,594) B (N=2,879) C (N=3,534) D (N=6,319)
Total deaths, n (%)
HR for total deaths relative to GOLD Group A
HR for total deaths relative to GOLD Group C
172 (4.8)
–
0.85 (P=0.12)
189 (6.6)
1.39 (P=0.002)
1.18 (P=0.11)
197 (5.6)
1.18 (P=0.12)
–
690 (10.9)
2.38 (P0.0001)
2.02 (P0.0001)
Total number of respiratory deaths, n (%) 11 (0.3) 22 (0.8) 55 (1.6) 265 (4.2)
HR for respiratory deaths relative to GOLD Group A – 2.52 (P=0.01) 5.14 (P0.0001) 14.40 (P0.0001)
HR for respiratory deaths relative to GOLD Group C 0.19 (P0.0001) 0.49 (P=0.005) – 2.80 (P0.0001)
MACE deaths, n (%) 44 (1.2) 64 (2.2) 45 (1.3) 166 (2.6)
HR for MACE deaths relative to GOLD Group A – 1.83 (P=0.002) 1.05 (P=0.81) 2.23 (P0.0001)
HR for MACE deaths relative to GOLD Group C 0.95 (P=0.81) 1.74 (P=0.004) – 2.12 (P0.0001)
MI deaths, n (%) 4 (0.1) 5 (0.2) 0 14 (0.2)
HR for MI deaths relative to GOLD Group A
HR for MI deaths relative to GOLD Group C
–
–
1.58 (P=0.50)
–
0
–
2.09 (P=0.19)
–
Patients with MACE, n (%) 122 (3.4) 119 (4.1) 109 (3.1) 269 (4.3)
HR for MACE relative to GOLD Group A
HR for MACE relative to GOLD Group C
–
1.11 (P=0.45)
1.23 (P=0.10)
1.36 (P=0.02)
0.91 (P=0.45)
–
1.30 (P=0.02)
1.43 (P=0.002)
Patients with MI event, n (%)
HR for MI event relative to GOLD Group A
HR for MI event relative to GOLD Group C
46 (1.3)
–
1.51 (P=0.08)
33 (1.2)
0.91 (P=0.67)
1.37 (P=0.21)
30 (0.9)
0.66 (P=0.08)
–
81 (1.3)
1.04 (P=0.85)
1.56 (P=0.04)
Patients with hospitalized exacerbation, n (%) 229 (6.4) 297 (10.3) 533 (15.1) 1,379 (21.8)
HR for hospitalized exacerbation relative to GOLD Group A – 1.67 (P0.0001) 2.48 (P0.0001) 3.85 (P0.0001)
HR for hospitalized exacerbation relative to GOLD Group C 0.40 (P0.0001) 0.68 (P0.0001) – 1.56 (P0.0001)
Abbreviations: CV, cardiovascular; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; MACE, major adverse cardiovascular event; 
MI, myocardial infarction.
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Table 4 All-cause mortality by GOLD group and by pulmonary and cardiac therapy at baseline
All-cause deaths GOLD group
A (N=3,594) B (N=2,879) C (N=3,534) D (N=6,319)
Mortality by pulmonary therapy
Number of patients with LAMA treatment (without LABA or ICS), n
Deaths, n (%)
538
30 (5.6)
368
24 (6.5)
336
15 (4.5)
453
40 (8.8)
HR relative to GOLD Group A – 1.17 (P=0.57) 0.79 (P=0.45) 1.59 (P=0.06)
HR relative to GOLD Group C 1.27 (P=0.45) 1.49 (P=0.23) – 2.02 (P=0.02)
Number of patients with LAMA, LABA, and ICS (triple therapy) treatment, n
Deaths, n (%)
911
40 (4.4)
723
55 (7.6)
1,122
61 (5.4)
2,053
244 (11.9)
HR relative to GOLD Group A – 1.77 (P=0.01) 1.25 (P=0.28) 2.85 (P0.0001)
HR relative to GOLD Group C 0.80 (P=0.28) 1.42 (P=0.06) – 2.29 (P0.0001)
Mortality by CV therapy
Number of patients with any CV therapy, n
Deaths, n (%)
1,886
108 (5.7)
1,662
129 (7.8)
1,646
113 (6.9)
3,185
387 (12.2)
HR relative to GOLD Group A – 1.37 (P=0.01) 1.20 (P=0.17) 2.22 (P0.0001)
HR relative to GOLD Group C 0.83 (P=0.17) 1.14 (P=0.31) – 1.85 (P0.0001)
Number of patients without CV therapy, n
Deaths, n (%)
1,700
64 (3.8)
1,210
60 (5.0)
1,882
83 (4.4)
3,124
302 (9.7)
HR relative to GOLD Group A – 1.32 (P=0.12) 1.19 (P=0.30) 2.67 (P0.0001)
HR relative to GOLD Group C 0.84 (P=0.30) 1.11 (P=0.53) – 2.25 (P0.0001)
Note: Patients with LABA and ICS but without LAMA at baseline are not included in this analysis, as they received triple therapy during the trial.
Abbreviations: CV, cardiovascular; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; ICS, inhaled corticosteroid; LABA, long-acting 
β2-agonist; LAMA, long-acting muscarinic antagonist.
levels (high risk = more symptoms), Group D had the 
highest mortality, followed by Group B, with the high-
est proportion of CV death in Group D. Patients classi-
fied under Group B were using more CV treatments at 
baseline than any other group, and their risk of CV death 
was significantly higher than in Groups C or A. Group A 
patients, however, received proportionally more β-blockers 
than other groups (in particular Groups C and D), 
possibly due to more widespread prescription owing to their 
mild obstruction and low dyspnea. A significant number of 
Group A patients received baseline medication, and 25% 
were treated with triple therapy at baseline.
There were more respiratory deaths in Groups C and D 
than B, even though patients in Group B were still sig-
nificantly more likely to die from a respiratory cause than 
patients in Group A. In TIOSPIR®, the imbalance of CV 
adverse event outcomes seen in patients from GOLD Group B 
was therefore not reflected in respiratory mortality; however, 
when patients were categorized by the old GOLD stages, the 
risk of death from respiratory causes significantly increased 
with increasing stage level.
Data from TIOSPIR® have supported the hypothesis that 
GOLD Group B, which includes patients with more symp-
toms but better lung function, reflects a group of patients 
with underlying CV comorbidities, as was seen in a Danish 
study.3 Lange et al reported that in their patient cohort, 
patients classified as GOLD Group B had a poorer survival 
than those in Group C, in particular due to CV causes (2.9% 
vs 0.5%; 3-year mortality rate; P0.001).3 Groups B and D, 
the more symptomatic groups, had more CV deaths than 
Groups A and C, the less symptomatic groups. Our results 
have highlighted the importance of symptoms, including 
dyspnea, as an indicator for increased CV risk, suggesting 
that these patients should be monitored closely for CV disease 
and accordingly receive appropriate management. Defining 
patients by the 2014 GOLD classification adds a new dimen-
sion to the risks and causes of mortality, and our data suggest 
that the mMRC dyspnea scale may be a good indicator of CV 
risk in patients with a contrast in intensity of dyspnea and 
severity of airway obstruction based on FEV
1
.
Our data have also confirmed the previous reports which 
indicate that using dyspnea as a measure of disease severity 
in the staging of COPD is a better predictor of 5-year survival 
than airway obstruction (FEV
1
).8,9 Therefore, particular 
attention should be paid to patients classified as GOLD B 
according to the 2011 guidelines, who have a high mMRC 
dyspnea score, as these patients represent a relatively high 
risk of underlying CV comorbidity. CV diseases are the most 
frequent, as well as the most important, COPD comorbidity,1 
but often remain undiagnosed.10 CV comorbidities, such as 
atrial fibrillation, heart failure, and MI, result in breathless-
ness, making diagnosis and treatment particularly challenging 
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for the physician.1 Furthermore, heart failure (HR =1.9; 95% 
confidence interval [CI] =1.3–2.9), ischemic heart disease 
(HR =1.5; 95% CI =1.1–2.0), and heart disease (HR =1.5; 
95% CI =1.2–2.0) all have also been shown to increase the 
odds of mortality when coexistent with COPD,11 which may 
explain why Group B patients exhibited a higher risk of CV 
mortality in TIOSPIR®.
Data from TIOSPIR® have shown that all-cause mortality 
was higher in Group B patients than the patients from Groups A 
and C, regardless of whether the patients were receiving 
LAMA only versus triple therapy at baseline and whether 
or not they were treated with CV medication at baseline. 
On the other hand, a pooled analysis of data from Spanish 
patient cohorts12 showed that in their patient population, there 
was a better long-term survival of GOLD Group B patients 
compared to Group C patients and that this followed the trend 
seen with the old GOLD Stages I–IV. Both the Spanish and 
Danish studies did observe, however, that the 2011 GOLD 
grading classification produced an uneven split of patients 
with COPD, with more patients in the extreme (low risk, 
fewer symptoms, or high risk, more symptoms) Groups A 
and D than the mixed Groups B and C. This uneven split was 
also observed in TIOSPIR®, with more patients in Groups 
D and A than B and C. In the UPLIFT® trial, mortality also 
increased from Groups A–D, but there was no difference in 
the overall mortality of Groups B and C.13
The TIOSPIR® trial has several strengths. It was a large 
trial with 34,000 patient-years’ exposure to tiotropium, 
powered to precisely estimate the rates of death and exacerba-
tions: Tiotropium Respimat® was not inferior to tiotropium 
HandiHaler® in terms of all-cause mortality, and the risk of 
CV mortality or MACE did not significantly differ between 
the two devices.6 The high vital status follow-up rates (99.7%) 
allow little leeway for bias owing to differential follow-up. 
In addition, patients in TIOSPIR® were permitted to use all 
respiratory medications except other inhaled anticholinergics. 
Therefore, the trial results reflect those likely to be achieved 
in routine clinical practice. Although this is a prospective 
study, the statistical power is high due to the large study 
population, covering all GOLD groups and – with more than 
3,500 patients in GOLD Group C and over 6,000 patients in 
Group D – including patients worldwide.
According to the current GOLD guidelines, the sever-
ity assessment of COPD disease involves calculation of 
the risk of exacerbation with one of the three methods: 
1) airflow limitation GOLD grade (GOLD 1/2 [FEV
1
 50% 
predicted]: low risk; GOLD 3/4 [FEV
1 
50% predicted]: high 
risk); 2) number of exacerbations within the previous year 
(0 or 1: low risk; 2: high risk); and 3) one or more hospital-
izations (1 severe exacerbation) within the previous year.1 
The guidelines stipulate that the method which provides the 
highest risk should be used. A limitation of this study was 
that severe exacerbation history (resulting in hospitalizations) 
was not collected at baseline, and patients were classified 
according to their history of exacerbations requiring treat-
ment with antibiotics and/or systemic steroids, in line with the 
GOLD 2011 categorization system.2 However, exacerbation 
history remains the single best predictor of future exacerba-
tions, thus validating the use of actual exacerbation rate in 
assessing exacerbation risk.14
Pretrial mMRC score was also used, which – though it 
can be modified by therapy – reflects decisions made upon 
selecting treatments. The COPD assessment test (CAT) score 
was not collected in the TIOSPIR® trial, and it was previously 
shown that the CAT and mMRC symptom cut-points cannot 
be used interchangeably,15 making it difficult for clinicians 
and researchers alike to evaluate the GOLD system. We 
believe that the mMRC cut-point is more readily available 
to clinicians, allowing for a wider applicability of the data 
presented in this analysis.
Another limitation of the TIOSPIR® trial is that patients 
with unstable CV conditions or moderate or severe renal 
impairment were excluded, so the results cannot be extended 
to such patients. However, ~10% of patients in TIOSPIR® had 
prior cardiac arrhythmias and ~20% had prior MI, ischemic 
heart disease, or coronary artery disease.6
Conclusion
The TIOSPIR® data support the observation that GOLD 
Group B patients, with more symptoms and better lung 
function, have more underlying CV comorbidities as 
well as an increased CV mortality compared to Groups A 
and C, and suggest that this is the case regardless of CV 
and pulmonary therapy at baseline. Although respiratory 
deaths increased according to GOLD group (A–D), particu-
lar attention should be given to patients with high mMRC 
dyspnea scores who may be at increased risk of CV events 
and mortality.
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Table S1 Number of patients with GOLD Stage I/II–IV at baseline by GOLD Group A–D at baseline
GOLD stage GOLD group Total
A B C D
I/II
N (%)
Row %
Column %
3,594 (22.0)
45.9
100.0
2,871 (17.6)
36.8
100.0
564 (3.5)
7.2
16.0
798 (4.9)
10.2
12.6
7,835 (48.0)
III
N (%)
Row %
Column %
0 (0.0)
0.0
0.0
0 (0.0)
0.0
0.0
2,522 (15.5)
37.8
71.4
4,157 (25.5)
62.2
65.8
6,679 (40.9)
IV
N (%)
Row %
Column %
0 (0.0)
0.0
0.0
0 (0.0)
0.0
0.0
448 (2.7)
24.7
12.7
1,364 (8.4)
75.3
21.6
1,812 (11.1)
Total
N (%) 3,594 (22.0) 2,879 (17.6) 3,534 (21.7) 6,319 (38.7) 16,326 (100)
Abbreviation: GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Table S2 Patient baseline characteristics by GOLD stage
Baseline characteristic GOLD stage
I/II (N=7,835) III (N=6,679) IV (N=1,812)
Follow-up duration (days), mean (SD) 847 (130) 835 (148) 804 (185)
Post-BD FEV1 (L), mean (SD)
Predicted (%), mean (SD)
1.648 (0.412)
60.1 (6.3)
1.126 (0.283)
40.3 (5.7)
0.708 (0.172)
24.3 (4.1)
Post-BD FVC (L), mean (SD)
Ratio of FEV1 to FVC
3.018 (0.819)
0.556 (0.085)
2.541 (0.746)
0.458 (0.098)
2.013 (0.687)
0.373 (0.098)
Sex
Male 5,293 (67.6) 4,896 (73.3) 1,481 (81.7)
Race
White
Black
Asian
Unknown
6,682 (85.3)
102 (1.3)
820 (10.5)
231 (2.9)
5,389 (80.7)
112 (1.7)
1,046 (15.7)
132 (2.0)
1,309 (72.2)
29 (1.6)
434 (24.0)
40 (2.2)
Age (years), mean (SD) 65.2 (9.4) 65.2 (8.8) 63.6 (8.4)
BMI (kg/m2), mean (SD) 27.1 (5.6) 25.7 (5.7) 23.8 (5.3)
Current smoker 3,143 (40.1) 2,472 (37.0) 600 (33.1)
Smoking history (pack years), mean (SD) 43.3 (24.7) 44.4 (24.8) 44.3 (25.2)
Medical history
Stroke
MI
IHD/CAD
Cardiac arrhythmia
202 (2.6)
489 (6.2)
1,222 (15.6)
838 (10.7)
137 (2.1)
410 (6.1)
1,077 (16.1)
732 (11.0)
36 (2.0)
91 (5.0)
226 (12.5)
183 (10.1)
Note: Data are n (%) unless otherwise stated.
Abbreviations: BD, bronchodilator; BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease; IHD/CAD, ischemic heart disease/coronary artery disease; MI, myocardial infarction; SD, standard deviation.
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Table S3 Type of baseline pulmonary and CV medication use categorized by GOLD stage
Baseline medication GOLD stage
I/II (N=7,835) III (N=6,679) IV (N=1,812)
Patients with pulmonary medication 7,007 (89.4) 6,155 (92.2) 1,674 (92.4)
LAMA (without LABA and ICS) 1,034 (13.2) 569 (8.5) 92 (5.1)
LABA and ICS (without LAMA) 1,642 (21.0) 1,594 (23.9) 478 (26.4)
LABA + ICS + LAMA (triple therapy) 2,034 (26.0) 2,179 (32.6) 596 (32.9)
Patients with CV medication 4,287 (54.7) 3,344 (50.1) 748 (41.3)
β-Blockers 1,295 (16.5) 917 (13.7) 150 (8.3)
Calcium channel blockers 1,485 (19.0) 1,140 (17.1) 276 (15.2)
ACE inhibitors 1,806 (23.1) 1,329 (19.9) 281 (15.5)
ARBs 1,026 (13.1) 682 (10.2) 138 (7.6)
Acetylsalicylic acid 1,640 (20.9) 1,267 (19.0) 262 (14.5)
Nitrates 355 (4.5) 257 (3.8) 70 (3.9)
Notes: Data are n (%). The group with the largest proportion is shown in bold.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CV, cardiovascular; GOLD, Global Initiative for Chronic Obstructive Lung 
Disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
Table S4 CV outcomes and patient mortality by GOLD stage
Deaths and outcomes GOLD stage
I/II (N=7,835) III (N=6,679) IV (N=1,812)
Total deaths, n (%)
HR for total deaths relative to GOLD Stage I/II
441 (5.6)
–
552 (8.3)
1.49 (P0.0001)
255 (14.1)
2.65 (P0.0001)
Total number of respiratory deaths, n (%) 51 (0.7) 169 (2.5) 133 (7.3)
HR for respiratory death relative to GOLD Stage I/II – 3.95 (P0.0001) 12.02 (P0.0001)
MACE deaths, n (%) 130 (1.7) 135 (2.0) 54 (3.0)
HR for MACE deaths relative to GOLD Stage I/II – 1.24 (P=0.085) 1.90 (P0.0001)
MI deaths, n (%) 10 (0.1) 8 (0.1) 5 (0.3)
HR for MI deaths relative to GOLD Stage I/II – 0.95 (P=0.92) 2.30 (P=0.13)
Patients with MACE, n (%) 288 (3.7) 252 (3.8) 79 (4.4)
HR for MACE relative to GOLD Stage I/II – 1.03 (P=0.72) 1.25 (P=0.08)
Patients with MI event, n (%)
HR for MI event relative to GOLD Stage I/II
91 (1.2)
–
75 (1.1)
0.97 (P=0.86)
24 (1.3)
1.21 (P=0.42)
Patients with hospitalized exacerbation, n (%) 700 (8.9) 1,203 (18.0) 535 (29.5)
HR for hospitalized exacerbation relative to GOLD Stage I/II – 2.12 (P0.0001) 3.92 (P0.0001)
Abbreviations: CV, cardiovascular; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; MACE, major adverse cardiovascular event; 
MI, myocardial infarction.
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Table S5 All-cause mortality by GOLD stage and by pulmonary and cardiac therapy at baseline
All-cause deaths GOLD stage
I/II (N=7,835) III (N=6,679) IV (N=1,812)
Mortality by pulmonary therapy
Number of patients with LAMA treatment (without LABA or ICS), n
Deaths, n (%)
1,034
59 (5.7)
569
42 (7.4)
92
8 (8.7)
HR relative to GOLD Stage I/II – 1.29 (P=0.21) 1.52 (P=0.27)
Number of patients with LAMA, LABA, and ICS (triple therapy) treatment, n
Deaths, n (%)
2,034
118 (5.8)
2,179
180 (8.3)
596
102 (17.1)
HR relative to GOLD Stage I/II – 1.44 (P=0.002) 3.16 (P0.0001)
Mortality by CV therapy
Number of patients with any CV therapy, n
Deaths, n (%)
4,287
291 (6.8)
3,344
 333 (10.0)
748
113 (15.1)
HR relative to GOLD Stage I/II – 1.49 (P0.0001) 2.34 (P0.0001)
Number of patients without CV therapy, n
Deaths, n (%)
3,532
150 (4.2)
3,324
217 (6.5)
1,060
142 (13.4)
HR relative to GOLD Stage I/II – 1.56 (P0.0001) 3.36 (P0.0001)
Abbreviations: CV, cardiovascular; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; ICS, inhaled corticosteroid; LABA, long-acting 
β2-agonist; LAMA, long-acting muscarinic antagonist.
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